Drug Reference Index  by unknown
JOURNAL OF THORACIC ONCOLOGY
Drug Reference Index
ALK TKIs – abstracts: 2IN, 6IN, 88IN, 89IN
Actinomycin D – abstract: 289P
Amifostine – abstracts: 51IN, 191PD, 200P
Amrubicin – abstract: 12IN
Angiogenesis inhibitors – abstracts: 2IN, 12IN, 87IN
Anti-miR agents – abstract: 55IN
Aprepitant – abstract: 49IN
ASA404 – abstract: 83IN
Aurora A inhibitors – abstract: 28IN
Aurora B inhibitors – abstract: 28IN
Bcl-2 inhibitors – abstract: 2IN
Bevacizumab – abstracts: 7IN, 12IN, 20IN, 21IN, 69IN, 77IN, 83IN,
84IN, 89IN, 134O, 154O, 210O, 211O, 212O, 213O, 237P, 239P,
246P, 247P, 255P
BI 6727 – abstract: 28IN
BI 811283 – abstract: 28IN
BIBF1120 – abstract: 87IN
BIBW2992 – abstracts: 6IN, 229P, 230P
Bleomycin – abstract: 5IN
BMS-275291 – abstract: 14IN
Bortezomib – abstracts: 69IN, 110P, 206O
Bosutinib – abstract: 14IN
Carboplatin – abstracts: 6IN, 7IN, 14IN, 20IN, 21IN, 34IN, 43IN, 46IN,
51IN, 54IN, 69IN, 83IN, 184O, 190PD, 205O, 212O, 225PD, 231P,
232P, 247P, 250P, 255P, 256P, 259P, 266O, 276P, 280P
Cediranib – abstract: 87IN
Cetuximab – abstracts: 20IN, 21IN, 74IN, 77IN, 83IN
Cisplatin – abstracts: 3IN, 5IN, 6IN, 8IN, 9IN, 12IN, 21IN, 27IN, 39IN,
46IN, 47IN, 49IN, 54IN, 69IN, 77IN, 84IN, 85IN, 88IN, 134O,
135O, 142PD, 174PD, 175PD, 179P, 183O, 184O, 191PD, 197P,
200P, 202O, 217PD, 230P, 240P, 247P, 249P, 251P, 256P, 257P,
258P, 259P, 260P, 263O, 266O, 270P, 274P, 275P, 276P, 277P,
278P, 279P, 294P
cMET inhibitors – abstract: 89IN
Cyclopamine – abstract: 29IN
Cyclophosphamide – abstracts: 8IN, 279P, 280P, 289P
Dasatinib – abstract: 14IN
Docetaxel – abstracts: 6IN, 7IN, 46IN, 53IN, 54IN, 77IN, 85IN, 87IN,
135O, 142PD, 143PD, 194P, 202O, 206O, 219PD, 220PD, 221PD,
230P, 231P, 236P, 256P
Doxorubicin – abstracts: 8IN, 253P, 279P, 280P, 289P
DR4 and DR5 agonists – abstract: 2IN
EGFR TKIs – abstracts: 2IN, 6IN, 20IN, 21IN, 41IN, 43IN, 52IN, 54IN,
59IN, 83IN, 84IN, 88IN, 89IN, 97PD, 137O, 201O, 203O, 227P,
256P, 228P
Epirubicin – abstract: 277P
Erlotinib – abstracts: 2IN, 6IN, 20IN, 21IN, 30IN, 40IN, 43IN, 53IN,
54IN, 69IN, 83IN, 85IN, 87IN, 89IN, 96O, 104P, 137O, 155O,
156O, 202O, 203O, 204O, 206O, 221PD, 224PD, 230P, 236P, 240P,
241P
Etoposide – abstracts: 8IN, 9IN, 12IN, 179P, 194P, 197P, 249P, 256P,
259P, 266P, 274P, 276P, 277P, 278P, 279P, 280P, 289P
Everolimus – abstracts: 53IN, 139O
Exemestane – abstract: 96O
FAK inhibitors – abstract: 14IN
FGF inhibitors – abstract: 2IN
Figitumumab – abstract: 217PD
Foretinib – abstract: 30IN
G-CSF – abstracts: 49IN, 206O, 237P
Gefitinib – abstracts: 6IN, 20IN, 53IN, 54IN, 69IN, 77IN, 83IN, 89IN,
104P, 137O, 201O, 205O, 230P, 241P, 245P, 260P
Gemcitabine – abstracts: 7IN, 46IN, 54IN, 69IN, 84IN, 134O, 194P,
196P, 217PD, 220PD, 225PD, 226PD, 230P, 232P, 236P, 250P,
253P, 258P, 259P
GLI inhibitors – abstract: 29IN
HDAC inhibitors – abstract: 110P, 294P
Hedgehog inhibitors – abstracts: 12IN, 29IN
Hsp90 inhibitors – abstract: 110P
IAP inhibitors – abstract: 2IN
Ifosfamide – abstracts: 8IN, 197P 277P, 278P, 289P
IGF-1 inhibitors – abstract: 2IN
IGF-IR inhibitor – abstracts: 2IN, 217PD
Inhibitors of the T790M mutation – abstracts: 40IN, 52IN
Interferon alpha – abstract: 5IN
Irinotecan – abstracts: 12IN, 248P, 260P, 279P
KX2-391 – abstract: 14IN
Lapatinib – abstract: 30IN
Locked nucleic acids (LNAs) – abstract: 55IN
MAGE-A3 immunotherapy – abstract: 3IN
Mitomycin C – abstracts: 69IN, 197P
Mitotic check point inhibitors – abstract: 2IN
Mitoxantrone – abstract: 3IN
MMP inhibitors – abstract: 14IN
Motesanib – abstract: 21IN
mTOR inhibitors – abstract: 53IN
Oxaliplatin – abstract: 235P
Paclitaxel – abstracts: 6IN, 7IN, 14IN, 20IN, 21IN, 34IN, 43IN, 47IN,
51IN, 54IN, 83IN, 191PD, 194P, 200P, 205O, 212O, 225PD, 229P,
231P, 250P, 255P, 256P
Palonosetron – abstract: 49IN
PARP inhibitors – abstract: 2IN
Pemetrexed – abstracts: 6IN, 12IN, 53IN, 69IN, 74IN, 84IN, 85IN, 87IN,
138O, 139O, 184O, 202O, 209O, 217PD, 221PD, 226P, 228P, 232P,
234P, 235P, 236P, 237P, 238P, 247P, 255P, 263O, 270P
PF00299804 – abstract: 6IN
PF-02341066 – abstracts: 6IN, 31IN
PF1066 – abstract: 2IN
PI3 kinase inhibitors – abstract: 53IN
PI3K/mTOR axis inhibitors – abstract: 53IN
Platinum compounds – abstracts: 21IN, 34IN, 39IN, 47IN, 53IN, 85IN,
89IN, 107P, 134O, 175PD, 194P, 196P, 204O, 206O, 209O, 222PD,
226PD, 227PD, 232P, 236P, 247P, 249P, 253P, 260P, 263O, 264,
276P, 278P
Plinabulin – abstract: 231P
Plk1 inhibitors – abstract: 28IN
Rapamycin – abstracts: 53IN, 176P
Recombinant EPO – abstract: 50IN
RTK inhibitors – abstract: 30IN
Saracatinib – abstract: 14IN
SMAC mimetics – abstract: 2IN
Sorafenib – abstracts: 21IN, 69IN, 83IN, 87IN, 155O, 156O
Src inhibitors – abstract: 14IN
Sunitinib – abstracts: 12IN, 87IN
Taxanes – abstracts: 12IN, 28IN, 53IN, 196P, 202O, 240P
Tegafur-uracil – abstract: 47IN
Thalidomide – abstract: 12IN
Topotecan – abstract: 12IN
Trastuzumab – abstract: 30IN
Vaccines BEC2 – abstract: 12IN
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Vandetanib – abstract: 87IN
Vatalanib – abstract: 69IN
VEGF-trap – abstract: 83IN
Vinblastine – abstract: 69IN
Vinca alkaloids – abstracts: 28IN, 69IN
Vincristine – abstracts: 279P, 280P, 289P
Vinflunine – abstract: 69IN
Vinorelbine – abstracts: 7IN, 21IN, 47IN, 69IN, 183O, 190PD, 194P,
225PD, 236P, 251P, 253P, 259P
Vorinostat – abstract: 69IN
XL647 – abstract: 6IN
Zoledronic acid – abstract: 253P
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